Physician profile
Ryan Sessums
NPI 1487115655
$4,430.63
in general payments reported to CMS, 2019-2025
16 companies · $4,431 in 2025
The $4,431 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,109 · Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,109.19 |
| Food and Beverage | $821.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,626.18 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $178.99 | 2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $89.02 | 2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $77.30 | 2025 | Dupixent |
| Baxter Healthcare | $62.51 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $55.11 | 2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $51.88 | 2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $49.23 | 2025 | |
| Merck Sharp & Dohme LLC | $43.41 | 2025 | Keytruda, Zerbaxa |
| Actelion Pharmaceuticals US, INC. | $40.48 | 2025 | Uptravi, Opsynvi, Opsumit |
| Verona Pharma, INC. | $38.57 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.40 | 2025 | Jascayd |
| Viatris Specialty LLC | $31.94 | 2025 | Yupelri |
| Fisher & Paykel Healthcare INC | $17.68 | 2025 | Fisher & Paykel Healthcare |
| Genzyme Corporation | $16.82 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.11 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sessums listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.